Update of the drug resistance mutations in HIV-1: Spring 2008.

作者信息

Johnson Victoria A, Brun-Vezinet Françoise, Clotet Bonaventura, Günthard Huldrych F, Kuritzkes Daniel R, Pillay Deenan, Schapiro Jonathan M, Richman Douglas D

机构信息

Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.

出版信息

Top HIV Med. 2008 Apr-May;16(1):62-8. doi: 10.1007/s11750-007-0034-z.

DOI:10.1007/s11750-007-0034-z

PMID:18441382

Abstract

摘要

相似文献

[1]

Update of the drug resistance mutations in HIV-1: Spring 2008.

Top HIV Med. 2008

[2]

Update of the drug resistance mutations in HIV-1: 2004.

Top HIV Med. 2004

[3]

Antiretroviral Resistance Mutations (revised April 2001).

HIV Clin Trials. 2001

[4]

Detection and significance of minority quasispecies of drug-resistant HIV-1.

J HIV Ther. 2006-12

[5]

Proviral DNA as a Target for HIV-1 Resistance Analysis.

Intervirology. 2015

[6]

Update of the drug resistance mutations in HIV-1: 2007.

Top HIV Med. 2007

[7]

Drug-resistant HIV infection among drug-naive patients in Israel.

Clin Infect Dis. 2005-1-15

[8]

Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

Virology. 2006-9-15

[9]

Pharmacological exposure and the development of drug resistance in HIV.

Antivir Ther. 2001

[10]

Current insights into reverse transcriptase inhibitor-associated resistance.

Antivir Ther. 2001

引用本文的文献

[1]

Structural and Functional Studies on HIV Protease: Mechanism of Action, Subtypes, Inhibitors, and Drug Resistance.

Methods Mol Biol. 2025

[2]

Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017).

EClinicalMedicine. 2020-1-5

[3]

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.

Afr J Lab Med. 2018-5-30

[4]

A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011.

PLoS One. 2017-5-11

[5]

Resistance mechanism of human immunodeficiency virus type-1 protease to inhibitors: A molecular dynamic approach.

Mol Biol Res Commun. 2014-12

[6]

Comparison of Newly Assembled Full Length HIV-1 Integrase With Prototype Foamy Virus Integrase: Structure-Function Prospective.

Jundishapur J Microbiol. 2016-2-15

[7]

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

PLoS One. 2016-1-5

[8]

Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.

Antimicrob Agents Chemother. 2015

[9]

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.

Clin Infect Dis. 2014-9-15

[10]

Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection.

Antimicrob Agents Chemother. 2013-5-13

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Update of the drug resistance mutations in HIV-1: Spring 2008.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献